These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 38414528)

  • 21. [Chinese expert consensus on standardized inhaler device application in stable chronic airway diseases (2023)].
    Inhalation Therapy and Respiratory Rehabilitation Group, Respiratory Equipment Committee of China Association of Medical Equipment
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Nov; 46(11):1055-1067. PubMed ID: 37914418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery.
    Shen AM; Minko T
    J Control Release; 2020 Oct; 326():222-244. PubMed ID: 32681948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhalation delivery of protein therapeutics.
    Kane C; O'Neil K; Conk M; Picha K
    Inflamm Allergy Drug Targets; 2013 Apr; 12(2):81-7. PubMed ID: 23517644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nanotechnology approaches for inhalation treatment of lung diseases.
    Kuzmov A; Minko T
    J Control Release; 2015 Dec; 219():500-518. PubMed ID: 26297206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipid-based pulmonary delivery system: a review and future considerations of formulation strategies and limitations.
    Ngan CL; Asmawi AA
    Drug Deliv Transl Res; 2018 Oct; 8(5):1527-1544. PubMed ID: 29881970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pulmonary drug delivery: a role for polymeric nanoparticles?
    d'Angelo I; Conte C; Miro A; Quaglia F; Ungaro F
    Curr Top Med Chem; 2015; 15(4):386-400. PubMed ID: 25579350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanoparticle-Based Drug Delivery System: The Magic Bullet for the Treatment of Chronic Pulmonary Diseases.
    Pramanik S; Mohanto S; Manne R; Rajendran RR; Deepak A; Edapully SJ; Patil T; Katari O
    Mol Pharm; 2021 Oct; 18(10):3671-3718. PubMed ID: 34491754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhaled lipid nanocarriers for pulmonary delivery of glucocorticoids: Previous strategies, recent advances and key factors description.
    Altube MJ; Perez N; Romero EL; Morilla MJ; Higa LH; Perez AP
    Int J Pharm; 2023 Jul; 642():123146. PubMed ID: 37330156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nanoparticle-Based Inhalation Therapy for Pulmonary Diseases.
    Yadav D; Wairagu PM; Kwak M; Jin JO
    Curr Drug Metab; 2022; 23(11):882-896. PubMed ID: 35927812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disease guided optimization of the respiratory delivery of microparticulate formulations.
    Xie Y; Zeng P; Wiedmann TS
    Expert Opin Drug Deliv; 2008 Mar; 5(3):269-89. PubMed ID: 18318650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of pulmonary diseases on the fate of inhaled medicines--a review.
    Wang YB; Watts AB; Peters JI; Williams RO
    Int J Pharm; 2014 Jan; 461(1-2):112-28. PubMed ID: 24291124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors Affecting Drug Exposure after Inhalation.
    Nováková A; Šíma M; Slanař O
    Prague Med Rep; 2022; 123(3):129-139. PubMed ID: 36107443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.
    Willis L; Hayes D; Mansour HM
    Lung; 2012 Jun; 190(3):251-62. PubMed ID: 22274758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carriers for the targeted delivery of aerosolized macromolecules for pulmonary pathologies.
    Osman N; Kaneko K; Carini V; Saleem I
    Expert Opin Drug Deliv; 2018 Aug; 15(8):821-834. PubMed ID: 30021074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in the development of microparticles for pulmonary administration.
    Jain H; Bairagi A; Srivastava S; Singh SB; Mehra NK
    Drug Discov Today; 2020 Oct; 25(10):1865-1872. PubMed ID: 32712311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disposition and safety of inhaled biodegradable nanomedicines: Opportunities and challenges.
    Haque S; Whittaker MR; McIntosh MP; Pouton CW; Kaminskas LM
    Nanomedicine; 2016 Aug; 12(6):1703-24. PubMed ID: 27033834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dry powder inhalers in COPD, lung inflammation and pulmonary infections.
    Muralidharan P; Hayes D; Mansour HM
    Expert Opin Drug Deliv; 2015 Jun; 12(6):947-62. PubMed ID: 25388926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhaled RNA Therapeutics for Obstructive Airway Diseases: Recent Advances and Future Prospects.
    Xu Y; Thakur A; Zhang Y; Foged C
    Pharmaceutics; 2021 Jan; 13(2):. PubMed ID: 33525500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contemporary Formulation Development for Inhaled Pharmaceuticals.
    Sou T; Bergström CAS
    J Pharm Sci; 2021 Jan; 110(1):66-86. PubMed ID: 32916138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and evaluation of novel inhalable sildenafil citrate spray-dried microparticles for pulmonary arterial hypertension.
    Shahin HI; Vinjamuri BP; Mahmoud AA; Shamma RN; Mansour SM; Ammar HO; Ghorab MM; Chougule MB; Chablani L
    J Control Release; 2019 May; 302():126-139. PubMed ID: 30940497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.